21 results on '"Latouche, Jean-Baptiste"'
Search Results
2. Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia.
- Author
-
Sugita, Mayumi, Yamazaki, Takahiro, Alhomoud, Mohammad, Martinet, Jérémie, Latouche, Jean-Baptiste, Golden, Encouse, Boyer, Olivier, Van Besien, Koen, Formenti, Silvia C., Galluzzi, Lorenzo, and Guzman, Monica L.
- Published
- 2023
- Full Text
- View/download PDF
3. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
- Author
-
Hamieh, Mohamad, Chatillon, Jean-François, Dupel, Estelle, Bayeux, Florence, Fauquembergue, Emilie, Maby, Pauline, Drouet, Aurelie, Duval-Modeste, Anne-Bénédicte, Adriouch, Sahil, Boyer, Olivier, and Latouche, Jean-Baptiste
- Subjects
CYTOTOXIC T cells ,ANTIGEN presenting cells ,T cells ,MELANOMA ,IMMUNOTHERAPY - Abstract
Adoptive immunotherapy based on the transfer of anti-tumor cytotoxic T lymphocytes (CTLs) is a promising strategy to cure cancers. However, rapid expansion of numerous highly functional CTLs with long-lived features remains a challenge. Here, we constructed NIH/3T3 mouse fibroblast-based artificial antigen presenting cells (AAPCs) and precisely evaluated their ability to circumvent this difficulty. These AAPCs stably express the essential molecules involved in CTL activation in the HLA-A*0201 context and an immunogenic HLA-A*0201 restricted analogue peptide derived from MART-1, an auto-antigen overexpressed in melanoma. Using these AAPCs and pentamer-based magnetic bead-sorting, we defined, in a preclinical setting, the optimal conditions to expand pure MART-1-specific CTLs. Numerous highly purified MART-1-specific CTLs were rapidly obtained from healthy donors and melanoma patients. Both TCR repertoire and CDR3 sequence analyses revealed that MART-1-specific CTL responses were similar to those reported in the literature and obtained with autologous or allogeneic presenting cells. These MART-1-specific CTLs were highly cytotoxic against HLA-A*0201
+ MART-1+ tumor cells. Moreover, they harbored a suitable phenotype for immunotherapy, with effector memory, central memory and, most importantly, stem cell-like memory T cell features. Notably, the cells harboring stem cell-like memory phenotype features were capable of self-renewal and of differentiation into potent effector anti-tumor T cells. These "off-the-shelf" AAPCs represent a unique tool to rapidly and easily expand large numbers of long-lived highly functional pure specific CTLs with stem cell-like memory T cell properties, for the development of efficient adoptive immunotherapy strategies against cancers. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.
- Author
-
Milcent, Benoit, Josseaume, Nathalie, Riller, Quentin, Giglioli, Ilenia, Rabia, Emilia, Deligne, Claire, Latouche, Jean-Baptiste, Hamieh, Mohamad, Couture, Alexandre, Toutirais, Olivier, Lone, Yu-Chun, Jeger-Madiot, Raphaël, Graff-Dubois, Stéphanie, Amorim, Sandy, Loiseau, Pascale, Toubert, Antoine, Brice, Pauline, Thieblemont, Catherine, Teillaud, Jean-Luc, and Sibéril, Sophie
- Subjects
T cells ,RITUXIMAB ,PEPTIDES ,BINDING site assay ,TRANSGENIC mice ,AUTOANTIGENS - Abstract
Preclinical and clinical studies have suggested that cancer treatment with antitumor antibodies induces a specific adaptive T cell response. A central role in this process has been attributed to CD4
+ T cells, but the relevant T cell epitopes, mostly derived from non-mutated self-antigens, are largely unknown. In this study, we have characterized human CD20-derived epitopes restricted by HLA-DR1, HLA-DR3, HLA-DR4, and HLA-DR7, and investigated whether T cell responses directed against CD20-derived peptides can be elicited in human HLA-DR-transgenic mice and human samples. Based on in vitro binding assays to recombinant human MHC II molecules and on in vivo immunization assays in H-2 KO/HLA-A2+ -DR1+ transgenic mice, we have identified 21 MHC II-restricted long peptides derived from intracellular, membrane, or extracellular domains of the human non-mutated CD20 protein that trigger in vitro IFN-γ production by PBMCs and splenocytes from healthy individuals and by PBMCs from follicular lymphoma patients. These CD20-derived MHC II-restricted peptides could serve as a therapeutic tool for improving and/or monitoring anti-CD20 T cell activity in patients treated with rituximab or other anti-CD20 antibodies. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
5. HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy.
- Author
-
Couture, Alexandre, Garnier, Anthony, Docagne, Fabian, Boyer, Olivier, Vivien, Denis, Le-Mauff, Brigitte, Latouche, Jean-Baptiste, and Toutirais, Olivier
- Subjects
HLA histocompatibility antigens ,CANCER immunotherapy ,CD4 antigen ,T cells ,LYMPHOCYTES ,CELLULAR therapy - Abstract
CD4
+ T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4+ T cells are another specialized subset that plays a fundamental role in the maintenance of immune tolerance to self-antigens. Manipulating effector or regulatory CD4+ T cells responses is a promising immunotherapy strategy for, respectively, chronical viral infections and cancer, or severe autoimmune diseases and transplantation. Adoptive cell therapy (ACT) is an emerging approach that necessitates defining robust and efficient methods for the in vitro expansion of antigen-specific T cells then infused into patients. To address this challenge, artificial antigen presenting cells (AAPCs) have been developed. They constitute a reliable and easily usable platform to stimulate and amplify antigen-specific CD4+ T cells. Here, we review the recent advances in understanding the functions of CD4+ T cells in immunity and in immune tolerance, and their use for ACT. We also describe the characteristics of different AAPC models and the way to improve their stimulating functions. Finally, we discuss the potential interest of these AAPCs, both as fundamental tools to decipher CD4+ T cell responses and as reagents to generate clinical grade antigen-specific CD4+ T cells for immunotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4+ T cells.
- Author
-
Garnier, Anthony, Hamieh, Mohamad, Drouet, Aurélie, Leprince, Jérôme, Vivien, Denis, Frébourg, Thierry, Le Mauff, Brigitte, Latouche, Jean‐Baptiste, and Toutirais, Olivier
- Abstract
Owing to their multiple immune functions, CD4+ T cells are of major interest for immunotherapy in chronic viral infections and cancer, as well as for severe autoimmune diseases and transplantation. Therefore, standardized methods allowing rapid generation of a large number of CD4+ T cells for adoptive immunotherapy are still awaited. We constructed stable artificial antigen‐presenting cells (AAPCs) derived from mouse fibroblasts. They were genetically modified to express human leukocyte antigen (HLA)‐DR molecules and the human accessory molecules B7.1, Intercellular adhesion molecule‐1 (ICAM‐1) and lymphocyte function‐associated antigen‐3 (LFA‐3). AAPCs expressing HLA‐DR1, HLA‐DR15 or HLA‐DR51 molecules and loaded with peptides derived from influenza hemagglutinin (HA), myelin basic protein (MBP) or factor VIII, respectively, activated specific CD4+ T‐cell clones more effectively than Epstein‐Barr virus (EBV)‐transformed B cells. We also showed that AAPCs were able to take up and process whole Ag proteins, and present epitopes to specific T cells. In primary cultures, AAPCs loaded with HA peptide allowed generation of specific Th1 lymphocytes from healthy donors as demonstrated by tetramer and intracellular cytokine staining. Although AAPCs were less effective than autologous peripheral blood mononuclear cells (PBMCs) to stimulate CD4+ T cells in primary culture, AAPCs were more potent to reactivate and expand memory Th1 cells in a strictly Ag‐dependent manner. As the availability of autologous APCs is limited, the AAPC system represents a stable and reliable tool to achieve clinically relevant numbers of CD4+ T cells for adoptive immunotherapy. For fundamental research in immunology, AAPCs are also useful to decipher mechanisms involved in the development of human CD4 T‐cell responses. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies.
- Author
-
Chatillon, Jean‐François, Hamieh, Mohamad, Bayeux, Florence, Abasq, Claire, Fauquembergue, Emilie, Drouet, Aurélie, Guisier, Florian, Latouche, Jean‐Baptiste, and Musette, Philippe
- Subjects
LYMPHOCYTES ,CELL-mediated cytotoxicity ,MELANOMA ,CELL receptors ,INTRACELLULAR tracking - Abstract
Adoptive transfer of in vitro activated and expanded antigen-specific cytotoxic T lymphocytes (CTLs) is a promising therapeutic strategy for infectious diseases and cancers. Obtaining in vitro a sufficient amount of highly specific cytotoxic cells and capable of retaining cytotoxic activity in vivo remains problematic. We studied the role of Toll-Like Receptor-8 (TLR8) engagement on peripheral CTLs activated with melanoma antigen MART-1-expressing artificial antigen-presenting cells (AAPCs). After a 3-week co-culture, 3-27% of specific CTLs were consistently obtained. CTLs expressed TLR8 in the intracellular compartment and at the cell surface. Specific CTLs activated with a TLR8 agonist (CL075) 24 h before the end of the culture displayed neither any change in their production levels of molecules involved in cytotoxicity (IFN-γ, Granzyme B, and TNF-α) nor major significant change in their cell surface phenotype. However, these TLR8-stimulated lymphocytes displayed increased cytotoxic activity against specific peptide-pulsed target cells related to an increase in specific anti-melanoma CTL functional avidity. TLR8 engagement on CTLs could, therefore, be useful in different immunotherapy strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li-Fraumeni syndrome with brain tumours.
- Author
-
Aury-Landas, Juliette, Bougeard, Gaëlle, Castel, Hélène, Hernandez-Vargas, Hector, Drouet, Aurélie, Latouche, Jean-Baptiste, Schouft, Marie-Thérèse, Férec, Claude, Leroux, Dominique, Lasset, Christine, Coupier, Isabelle, Caron, Olivier, Herceg, Zdenko, Frebourg, Thierry, and Flaman, Jean-Michel
- Subjects
LI-Fraumeni syndrome ,P53 protein ,DNA copy number variations ,GERM cells ,CHROMATIN - Abstract
Germline alterations of the tumour suppressor TP53 gene are detected approximately in 25% of the families suggestive of Li-Fraumeni syndrome (LFS), characterised by a genetic predisposition to a wide tumour spectrum, including soft-tissue sarcomas, osteosarcomas, premenopausal breast cancers, brain tumours, adrenocortical tumours, plexus choroid tumours, leukaemia and lung cancer. The aim of this study was to determine the contribution of germline copy number variations (CNVs) to LFS in families without detectable TP53 mutation. Using a custom-designed high-resolution array CGH, we evaluated the presence of rare germline CNVs in 64 patients fulfilling the Chompret criteria for LFS, but without any detectable TP53 alteration. In 15 unrelated patients, we detected 20 new CNVs absent in 600 controls. Remarkably, in four patients who had developed each brain tumour, the detected CNV overlap the KDM1A, MTA3, TRRAP or SIRT3 genes encoding p53 partners involved in histone methylation or acetylation. Focused analysis of SIRT3 showed that the CNV encompassing SIRT3 leads to SIRT3 overexpression, and that in vitro SIRT3 overexpression prevents apoptosis, increases G2/M and results in a hypermethylation of numerous genes. This study supports the causal role of germline alterations of genes involved in chromatin remodelling in genetic predisposition to cancer and, in particular, to brain tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer.
- Author
-
Sarafan-Vasseur, Nasrin, Sefrioui, David, Tougeron, David, Lamy, Aude, Blanchard, France, Pessot, Florence Le, Fiore, Frédéric Di, Michel, Pierre, Bézieau, Stéphane, Latouche, Jean-Baptiste, Frebourg, Thierry, and Sesboüé, Richard
- Subjects
HUMAN genetic variation ,GENETIC mutation ,GENETIC polymorphisms ,COLON cancer ,CELL culture ,MESSENGER RNA - Abstract
Background: The EGFR 3' untranslated region (UTR) harbors a polyadenine repeat which is polymorphic (A13/A14) and undergoes somatic deletions in microsatellite instability (MSI) colorectal cancer (CRC). These mutations could be oncogenic in colorectal tissue since they were shown to result into increased EGFR mRNA stability in CRC cell lines. Methods: First, we determined in a case control study including 429 CRC patients corresponding to different groups selected or not on age of tumor onset and/or familial history and/or MSI, whether or not, the germline EGFR A13/A14 polymorphism constitutes a genetic risk factor for CRC; second, we investigated the frequency of somatic mutations of this repeat in 179 CRC and their impact on EGFR expression. Results: No statistically significant difference in allelic frequencies of the EGFR polyA repeat polymorphism was observed between CRC patients and controls. Somatic mutations affecting the EGFR 3'UTR polyA tract were detected in 47/80 (58.8%) MSI CRC versus 0/99 microsatellite stable (MSS) tumors. Comparative analysis in 21 CRC samples of EGFR expression, between tumor and non malignant tissues, using two independent methods showed that somatic mutations of the EGFR polyA repeat did not result into an EGFR mRNA increase. Conclusion: Germline and somatic genetic variations occurring within the EGFR 3' UTR polyA tract have no impact on CRC genetic risk and EGFR expression, respectively. Genotyping of the EGFR polyA tract has no clinical utility to identify patients with a high risk for CRC or patients who could benefit from anti-EGFR antibodies [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Regulatory T Lymphocytes Are Associated with Less Aggressive Histologic Features in Microsatellite-Unstable Colorectal Cancers.
- Author
-
Tougeron, David, Maby, Pauline, Elie, Nicolas, Fauquembergue, Émilie, Le Pessot, Florence, Cornic, Marie, Sabourin, Jean-Christophe, Michel, Pierre, Frébourg, Thierry, and Latouche, Jean-Baptiste
- Subjects
COLON cancer ,T cells ,HISTOLOGY ,MICROSATELLITE repeats ,IMMUNOLOGY ,ADENOCARCINOMA ,ONCOLOGY research - Abstract
Background: Colorectal cancers (CRCs) with microsatellite instability (MSI) are associated with a good prognosis and a high density of tumor-infiltrating lymphocytes (TILs). We have undertaken to determine the link between TIL densities and MSI CRC histologic features. Patients and Methods: Using tissue microarrays, T-cell sub-population infiltration, including T cells (CD3), cytotoxic T cells (CD8) and regulatory T cells (FoxP3) were studied in 86 MSI CRCs. We separately analyzed TILs of the stromal and epithelial compartments in the tumor center, the tumoral invasion margin and associated normal tissue. Results: For FoxP3+ TIL density in the tumor center stromal compartment, we found a strong negative correlation with T4 stage (p = 0.01), node invasion (p<0.001) and VELIPI (vascular emboli, lymphatic invasion and perinervous invasion) criteria (p = 0.002). Conclusion: The strong correlation between regulatory T cell density and the absence of VELIPI criteria suggests that this sub-group of T cells is preferentially associated with less invasive tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
11. Pitfalls in the use of DGV for CNV interpretation.
- Author
-
Duclos, Aude, Charbonnier, Françoise, Chambon, Pascal, Latouche, Jean-Baptiste, Blavier, André, Redon, Richard, Frébourg, Thierry, and Flaman, Jean-Michel
- Published
- 2011
- Full Text
- View/download PDF
12. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations.
- Author
-
Tougeron, David, Fauquembergue, Emilie, Rouquette, Alexandre, Le Pessot, Florence, Sesboüé, Richard, Laurent, Michèle, Berthet, Pascaline, Mauillon, Jacques, Di Fiore, Frédéric, Sabourin, Jean-Christophe, Michel, Pierre, Tosi, Mario, Frébourg, Thierry, Latouche, Jean-Baptiste, Sesboüé, Richard, Laurent, Michèle, Di Fiore, Frédéric, and Frébourg, Thierry
- Published
- 2009
- Full Text
- View/download PDF
13. Gradual reduction of BUBR1 protein levels results in premature sister-chromatid separation then in aneuploidy.
- Author
-
Bohers, Elodie, Sarafan-Vasseur, Nasrin, Drouet, Aurélie, Paresy, Marianne, Latouche, Jean-Baptiste, Flaman, Jean-Michel, Sesboüé, Richard, and Frebourg, Thierry
- Subjects
ANEUPLOIDY ,GENETIC mutation ,SISTER chromatid exchange ,CHROMOSOMES ,PROTEINS - Abstract
Biallelic and heterozygous mutations of the BUB1B gene have been reported in mosaic variegated aneuploidy (MVA), a rare disorder characterized by constitutional mosaic aneuploidies associated to severe intrauterine growth retardation, microcephaly and, in most cases, to premature chromatid separation (PCS), highlighting the key role of human BUBR1 in chromosome segregation. To study the consequences of gradual reduction of the BUBR1 protein levels, inhibition of BUB1B expression in model cells was induced using short hairpin RNAs (shRNAs). We obtained stable shRNA-transduced HeLa cells displaying a gradient of residual BUBR1 protein (8.5, 10, 14, 58, and 77%), mimicking the situation of patients’ cells harboring one or two BUB1B mutations. Induction of PCS was detected in all transduced cells and its level was correlated to the decrease of BUBR1. Aneuploidy was clearly detected in cells with residual BUBR1 below 50%. Our data demonstrate that the function of the human BUBR1 protein in the spindle checkpoint is remarkably dosage-dependent and that the biological consequences of BUB1B expression reduction on premature chromatid separation and aneuploidy depend on the residual amount of BUBR1. This provides a biological explanation for the mode of inheritance of PCS, which is dominant, and of MVA, which can be recessive in some families and result from the combination of a null allele associated to a common hypomorphic allele in others. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
14. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
- Author
-
Gregor, Polly D., Wolchok, Jedd D., Turaga, Vandana, Latouche, Jean-Baptiste, Sadelain, Michel, Bacich, Dean, Heston, Warren D.W., Houghton, Alan N., and Scher, Howard I.
- Abstract
Prostate-specific membrane antigen (PSMA) is a prototypical differentiation antigen expressed on normal and neoplastic prostate epithelial cells, and on the neovasculature of many solid tumors. Monoclonal antibodies specific for PSMA are in development as therapeutic agents. Methodologies to actively immunize against PSMA may be limited by immunologic ignorance and/or tolerance that restrict the response to self-antigens. Our studies have previously shown that xenogeneic immunization with DNA vaccines encoding melanosomal differentiation antigens induces immunity in a mouse melanoma model. Here we apply this approach to PSMA to establish proof of principle in a mouse model. Immunization with xenogeneic human PSMA protein or DNA induced antibodies to both human and mouse PSMA in mice. Monoclonal antibodies specific for mouse PSMA were generated to analyze antibody isotypes and specificity for native and denatured PSMA at the clonal level. Most antibodies recognized denatured PSMA, but C57BL/6 mice immunized with xenogeneic PSMA DNA followed by a final boost with xenogeneic PSMA protein yielded autoantibodies that reacted with native folded mouse PSMA. Monoclonal antibodies were used to confirm the expression of PSMA protein in normal mouse kidney. These results establish the basis for clinical trials to test PSMA DNA vaccines in patients with solid tumors that either express PSMA directly or that depend on normal endothelial cells expressing PSMA for their continued growth. © 2005 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
15. The ABCs of artificial antigen presentation.
- Author
-
Kim, Jiyun V., Latouche, Jean-Baptiste, Rivière, Isabelle, and Sadelain, Michel
- Subjects
SYNTHETIC antigens ,THERAPEUTICS ,CELLULAR immunity ,T cells ,IMMUNOTHERAPY ,IMMUNE response ,TUMOR antigens ,ANTIGEN presenting cells - Abstract
Artificial antigen presentation aims to accelerate the establishment of therapeutic cellular immunity. Artificial antigen-presenting cells (AAPCs) and their cell-free substitutes are designed to stimulate the expansion and acquisition of optimal therapeutic features of T cells before therapeutic infusion, without the need for autologous antigen-presenting cells. Compelling recent advances include fibroblast AAPCs that process antigens, magnetic beads that are antigen specific, novel T-cell costimulatory combinations, the augmentation of therapeutic potency of adoptively transferred T lymphocytes by interleukin-15, and the safe use of dendritic cell-derived exosomes pulsed with tumor antigen. Whereas the safety and potency of the various systems warrant further preclinical and clinical studies, these emerging technologies are poised to have a major impact on adoptive T-cell therapy and the investigation of T cell-mediated immunity. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
16. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
- Author
-
Brentjens, Renier J., Latouche, Jean-Baptiste, Santos, Elmer, Marti, Francesc, Gong, Michael C., Lyddane, Clay, King, Philip D., Larson, Steven, Weiss, Mark, Riviere, Isabelle, and Sadelain, Michel
- Subjects
T cells ,B cell lymphoma ,ANTIGENS - Abstract
The genetic transfer of antigen receptors provides a means to rapidly generate autologous tumor-reactive T lymphocytes. However, recognition of tumor antigens by cytotoxic T cells is only one step towards effective cancer immunotherapy. Other crucial biological prerequisites must be fulfilled to expand tumor-reactive T cells that retain a functional phenotype, including in vivo cytolytic activity and the ability to travel to tumor sites without prematurely succumbing to apoptosis. We show that these requirements are met by expanding peripheral blood T cells genetically targeted to the CD19 antigen in the presence of CD80 and interleukin-15 (IL-15). T cells expanded in the presence of IL-15 uniquely persist in tumor-bearing severe combined immunodeficiency (SCID)-Beige mice and eradicate disseminated intramedullary tumors. Their anti-tumor activity is further enhanced by in vivo co-stimulation. In addition, transduced T cells from patients with chronic lymphocytic leukemia (CLL) effectively lyse autologous tumor cells. These findings strongly support the clinical feasibility of this therapeutic strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
17. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
- Author
-
Latouche, Jean-Baptiste and Sadelain, Michel
- Subjects
T cells ,HLA histocompatibility antigens ,CELLULAR therapy - Abstract
The adoptive transfer of antigen-specific cytotoxic T lymphocytes (CTLs) is a promising therapeutic approach for a number of diseases. To overcome the difficulty in generating specific CTLs, we established stable artificial antigen-presenting cells (AAPCs) that can be used to stimulate T cells of any patient of a given human leukocyte antigen (HLA) type. Mouse fibroblasts were retrovirally transduced with a single HLA -- peptide complex along with the human accessory molecules B7.1, ICAM-1, and LFA-3. These AAPCs consistently elicit strong stimulation and expansion of HLA-restricted CTLs. Owing to the high efficiency of retrovirus-mediated gene transfer, stable AAPCs can be readily engineered for any HLA molecule and any specific peptide. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
18. Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells.
- Author
-
Rabu, Catherine, Rangan, Laurie, Florenceau, Laetitia, Fortun, Agnès, Charpentier, Maud, Dupré, Emilie, Paolini, Léa, Beauvillain, Céline, Dupel, Estelle, Latouche, Jean-Baptiste, Adotevi, Olivier, Labarrière, Nathalie, and Lang, François
- Subjects
PEPTIDOMIMETICS ,CANCER vaccines ,T cells ,DENDRITIC cells ,TRANSGENIC mice ,HISTOCOMPATIBILITY class I antigens ,HEPATITIS B vaccines - Abstract
There is now a consensus that efficient peptide vaccination against cancer requires that peptides should (i) be exclusively presented by professional APC and (ii) stimulate both CD4 and CD8-specific T cell responses. To this aim, in recent trials, patients were vaccinated with pools of synthetic long peptides (SLP) (15-30 aa long) composed of a potential class I epitope(s) elongated at both ends with native antigen sequences to also provide a potential class II epitope(s). Using MELOE-1 as a model antigen, we present an alternative strategy consisting in linking selected class I and class II epitopes with an artificial cathepsin-sensitive linker to improve epitope processing and presentation by DC. We provide evidence that some linker sequences used in our artificial SLPs (aSLPs) could increase up to 100-fold the cross-presentation of class I epitopes to CD8-specific T cell clones when compared to cross-presentation of the corresponding native long peptide. Presentation of class II epitopes were only slightly increased. We confirmed this increased cross-presentation after in vitro stimulation of PBMC from healthy donors with aSLP and assessment of CD8-specific responses and also in vivo following aSLP vaccination of HLA*A0201/HLA-DRB0101 transgenic mice. Finally, we provide some evidence that vaccination with aSLP could inhibit the growth of transplanted tumors in mice. Our data thus support the use of such aSLPs in future cancer vaccination trials to improve anti-tumor CD8 T cell responses and therapeutic efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Frameshift mutations, neoantigens and tumor-specific CD8 T cells in microsatellite unstable colorectal cancers.
- Author
-
Maby, Pauline, Galon, Jérôme, and Latouche, Jean-Baptiste
- Subjects
FRAMESHIFT mutation ,GENETIC mutation ,T cells ,TUMORS ,MICROSATELLITE repeats ,COLON cancer - Abstract
Microsatellite unstable colorectal cancers (CRC) express frameshift mutation-derived tumor-specific neoantigens. We recently showed that: (i) frameshift mutations were correlated with tumor-infiltrating CD8+T cell density, (ii) neoantigen-specific cytotoxic T cells could be obtained in patients whose tumors harbored these mutations, underlining the interest of developing personalized immunotherapy strategies in these cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer.
- Author
-
Sarafan-Vasseur, Nasrin, Sefrioui, David, Tougeron, David, Lamy, Aude, Blanchard, France, Le Pessot, Florence, Di Fiore, Frédéric, Michel, Pierre, Bézieau, Stéphane, Latouche, Jean-Baptiste, Frebourg, Thierry, and Sesboüé, Richard
- Abstract
Background: The EGFR 3' untranslated region (UTR) harbors a polyadenine repeat which is polymorphic (A13/A14) and undergoes somatic deletions in microsatellite instability (MSI) colorectal cancer (CRC). These mutations could be oncogenic in colorectal tissue since they were shown to result into increased EGFR mRNA stability in CRC cell lines.Methods: First, we determined in a case control study including 429 CRC patients corresponding to different groups selected or not on age of tumor onset and/or familial history and/or MSI, whether or not, the germline EGFR A13/A14 polymorphism constitutes a genetic risk factor for CRC; second, we investigated the frequency of somatic mutations of this repeat in 179 CRC and their impact on EGFR expression.Results: No statistically significant difference in allelic frequencies of the EGFR polyA repeat polymorphism was observed between CRC patients and controls. Somatic mutations affecting the EGFR 3'UTR polyA tract were detected in 47/80 (58.8%) MSI CRC versus 0/99 microsatellite stable (MSS) tumors. Comparative analysis in 21 CRC samples of EGFR expression, between tumor and non malignant tissues, using two independent methods showed that somatic mutations of the EGFR polyA repeat did not result into an EGFR mRNA increase.Conclusion: Germline and somatic genetic variations occurring within the EGFR 3' UTR polyA tract have no impact on CRC genetic risk and EGFR expression, respectively. Genotyping of the EGFR polyA tract has no clinical utility to identify patients with a high risk for CRC or patients who could benefit from anti-EGFR antibodies. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
21. Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques.
- Author
-
Dumanchin, Cecile, Tournier, Isabelle, Martin, Cosette, Didic, Mira, Belliard, Serge, Carlander, Bertrand, Rouhart, François, Duyckaerts, Charles, Pellissier, Jean-François, Latouche, Jean Baptiste, Hannequin, Didier, Frebourg, Thierry, Tosi, Mario, and Campion, Dominique
- Abstract
We describe the biological consequences on PSEN1 exons 8 or 9 splicing and Aβ peptides production of four PSEN1 mutations associated with a phenotypic variant of Alzheimer disease, which includes cotton wool plaques and spastic paraparesis (CWP/SP). Two of these mutations (c.869-22_869-23ins18 and c.871A>C, p.T291P) are novel mutations located in intron 8 and exon 9, respectively. The c.869-22_869-23ins18 mutation caused exon 9 skipping whereas the c.871A>C (p.T291P) mutation showed only a modest effect on exon 9 skipping. The previously reported E280G and P264L mutations, located in exon 8, had no effect on mRNA splicing. Infection of cells with mutant T291P, E280G, or P264L cDNAs caused a variable increase in secreted Aβ42. We conclude that none of the previously proposed mechanisms, i.e. exceptionally large increases in secreted Aβ42 levels or loss of PSEN1 exons 8 or 9, provides complete explanation of the CWP/SP phenotype. © 2006 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.